FCRLM1 Inhibitors

FCRLM1 inhibitors encompass a diverse array of compounds that primarily target signaling molecules and pathways often associated with Fc receptors and their family members. The primary target of some of these inhibitors is the spleen tyrosine kinase (Syk), a pivotal component in the Fc receptor signaling. Syk inhibitors like R406, Piceatannol, and BAY 61-3606 have been noted for their ability to disrupt this signaling pathway. In a similar light, the Src family of kinases, instrumental in modulating various cellular processes including Fc receptor signaling, can be targeted by compounds such as PP2 and Dasatinib.

Other kinases and signaling molecules related to this broad category of receptors include Bruton's tyrosine kinase (BTK), for which Ibrutinib is a known inhibitor. The phosphoinositide 3-kinases (PI3K) pathway, which may have links to Fc receptor signaling, can be modulated by inhibitors like LY294002 and Wortmannin. Additionally, the MAPK/ERK pathway, linked to Fc receptor signaling, can be influenced by inhibitors such as PD98059 and U0126.Furthermore, the JAK3 kinase, another component that might be connected to Fc receptor signaling, can be inhibited by compounds like CP-690550. Lastly, SHIP1 phosphatase, a regulator of Fc receptor-mediated processes, is targetable by inhibitors like 3AC.